Sign In
Buy SRDX
$42.98
+0 (+0%)
At Close: Feb 24, 2026
Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2022 Results - Earnings Call Transcript
03:36pm, Wednesday, 27'th Jul 2022
Surmodics, Inc. (NASDAQ:SRDX ) Q3 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Tim Arens - Senior Vice President of
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
12:55pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27
08:30am, Tuesday, 19'th Jul 2022
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Catheter--Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27. Webcast is Live at 7:30 a.m. (CT)
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
03:34pm, Monday, 18'th Jul 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
01:09pm, Monday, 18'th Jul 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
02:52pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
12:20pm, Thursday, 16'th Jun 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
04:18pm, Friday, 29'th Apr 2022 Zacks Investment Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
01:33pm, Friday, 29'th Apr 2022
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q2 2022 Results - Earnings Call Transcript
03:42pm, Wednesday, 27'th Apr 2022
Surmodics, Inc. (NASDAQ:SRDX ) Q2 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Tim Arens - SVP, Finance & CFO Gary Maharaj - President & CEO Conference Call Participant
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
08:25am, Monday, 25'th Apr 2022
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
03:36pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
12:47pm, Tuesday, 22'nd Mar 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
